跳到正文
BioPharma Dive· Kristin Jensen·· 4 天前AI 评分46

Bristol Myers Squibb 研究负责人将离职,公司合并研发部门

Bristol Myers research chief to depart in ‘evolution’ of company’s structure

AI 导读

百时美施贵宝(Bristol Myers Squibb)将研究与开发部门合并,首席研究官 Robert Plenge 离职,首席医学官 Cristian Massacesi 自 1 月 1 日起出任新设的研发负责人。Plenge 将留任至 2027 年 3 月协助过渡。公司称此次架构“演进”旨在加快决策、改善管线管理并加速管线动能。

正文 · 原文

Opens in a new window Opens an external website Opens an external website in a new window

This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. Privacy Policy

Accept Deny Non-Essential

Storage Preferences

Skip to main content

Image 1: BioPharma Dive Logo

CONTINUE TO SITE ➞

Don’t miss tomorrow’s biopharma industry news

Let BioPharma Dive’s free newsletter keep you informed, straight from your inbox.

  • Daily Dive M-F

  • Commercialization Weekly Every Wednesday

  • Gene Therapy Weekly Every Thursday

  • Emerging Biotech Weekly Every Tuesday

  • By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Image 2: Informa TechTarget LogoInforma TechTarget|

Explore our brandsImage 3: Informa TechTarget BrandsAn Informa TechTarget Publication

Image 4: BioPharma Dive Logo

Sign upImage 5: menu

Search

Image 8Image 9

People also ask

An article fromImage 10: site logo

Dive Brief

Bristol Myers research chief to depart in ‘evolution’ of company’s structure

Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.

Published Nov. 12, 2026

By Kristin Jensen

Image 20: A white building entrance sign reads "Bristol Myers Squibb," with a barbed fence behind it surrounded by flowers.

Entrance sign of the Bristol Myers Squibb office in Summit, N.J., on Aug. 13, 2023. Alamy

Dive Brief:

  • Bristol Myers Squibb is combining its research and development departments, elevating Cristian Massacesi to the new job of head of R&D and saying goodbye to Chief Research Officer Robert Plenge, who came to the company with its $74 billion acquisition of Celgene.
  • Massacesi, currently chief medical officer and head of development, will take on the new post as of Jan. 1, Bristol Myers said Thursday. Plenge will stay with the company through March 2027 to help with the transition.
  • The “evolution” of the research and development organization will help speed decision making, improve portfolio management and “accelerate pipeline momentum,” Bristol Myers said. In the company’s statement, Plenge said he developed the new structure with Massacesi and is “confident it is the right path forward” for the company and patients.

Dive Insight:

Bristol Myers is reorganizing its research department as looming patent expirations threaten the sales of top medicines including the heart drug Eliquis, which brought in more than $14 billion last year.

To find products that can make up for lost sales, Bristol Myers is trying to make the most of drugs in development while looking outside for new prospects as well. There have been a few successes. In August, the company won approval for a multiple myeloma drug called Zenbexus. And another medicine for the condition, mezigdomide, delivered promising results in a study detailed in May.

But there have also been a few stumbles. A research failure set back a bid to widen the use of the heart drug Camzyos last year, and a trial of an experimental lung disease medicine disappointed investors in October. Meanwhile, a much-heralded schizophrenia medicine acquired in a $14 billion takeover of Karuna Therapeuticsfailed in a major study and has generated underwhelming sales so far.

In 2024, Bristol Myers said it would cut 6% of its workforce, consolidate facilities and trim its pipeline in a restructuring designed to strengthen its “long-term growth profile.” The company expanded the cost-cutting program the next year, saying it would slash another $2 billion by the end of 2027.

Since then, Bristol Myers has deepened its investment in artificial intelligence, betting on Anthropic’s Claude tool to tap all of its institutional knowledge. And it has an array of research readouts coming by the end of the first quarter of 2027. “We’ve made meaningful progress with our pipeline, and this evolution is about building on that momentum,” a company spokesperson said Thursday.

Plenge ran the inflammation and immunology business at Celgene before the 2019 acquisition. He then worked his way up in Bristol Myers, becoming head of research in July 2023.

Recommended Reading

Filed Under:Pharma

BioPharma Dive news delivered to your inbox

Get the free daily newsletter read by industry experts

Email:

  • Select Newsletter: - [x] Daily Dive M-F
  • Select Newsletter: - [x] Commercialization Weekly Every Wednesday
  • Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
  • Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
  • Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Sign up A valid email address is required. Please select at least one newsletter.

Image 30: Newsletter example on mobile

Editors’ picks

  • Image 31: A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.

Image 32: Image attribution tooltipAdeline Kon / BioPharma Dive/BioPharma Dive Image 33: Image attribution tooltip Deep Dive //Patent thickets

Drug patents protect pharma profits. Track when they’ll expire.

BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

By Jonathan Gardner • Updated Aug. 4, 2026

  • Image 34: A sign reading Food and Drug Administration hangs over a building entrance.

Image 35: Image attribution tooltipYujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration Image 36: Image attribution tooltip Tracker

5 FDA decisions to watch in the fourth quarter of 2025

Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.

By BioPharma Dive staff • Updated Sept. 30, 2025

Get the free newsletter

Subscribe to BioPharma Dive for top news, trends & analysis

Email:

  • Select Newsletter: - [x] Daily Dive M-F
  • Select Newsletter: - [x] Commercialization Weekly Every Wednesday
  • Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
  • Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
  • Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Sign up A valid email address is required. Please select at least one newsletter.

Take your knowledge further with

Sign up for the free newsletter.

Image 37 Interested? Explore more of what has to offer.

One-click newsletter signup

You’re all set

Thanks for signing up! Please keep an eye out for a confirmation email from newsletter@ittnewsletter.com To ensure we make it into your inbox regularly, add us to your allow list, mark us as a safe sender, or add us to your address book. Check out more from

Most Popular

  1. Image 38: A picture of buildings in Berlin. Drug price hikes in Germany could push US costs higher, study says
  2. Image 39: A stack of newspapers are seen against a blue background. AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
  3. Image 40: A horizontal photo depicting the top of the U.S. Capitol set against a blue sky. BIO unveils plan for US to remain biotech’s ‘global leader’
  4. Image 41: An illustration of beta amyloid plaques and tau in the brain London biotech Oyster harvests $60M for tau-targeting brain drugs

Company Announcements

View all | Post a press release

Events

View all | Promote an event

BioPharma Dive news delivered to your inbox

Get the free daily newsletter read by industry experts

Email:

  • Select Newsletter: - [x] Daily Dive M-F
  • Select Newsletter: - [x] Commercialization Weekly Every Wednesday
  • Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
  • Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
  • Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Sign up A valid email address is required. Please select at least one newsletter.

Image 42: Newsletter example on mobile

Company Announcements

View all | Post a press release

Cibus Therapeutics and Greenstone Biosciences Announce First Participant Dosed in Phase 1 Tria… From Greenstone Biosciences Inc November 11, 2026 Image 43: Greenstone Biosciences Inc logoSTART Expands its Global Early Phase Cancer Site Network into Italy Through Strategic Partners… From The START Center for Cancer Research November 03, 2026 Image 44: The START Center for Cancer Research logoAxion BioSystems Introduces Synexus, Bringing Richer Functional Insight to Drug Discovery From Axion BioSystems November 02, 2026 Image 45: Axion BioSystems logoCRIO and Eli Lilly and Company win SCDM Innovation Award for Alzheimer’s trial From CRIO October 27, 2026 Image 46: CRIO logo

Editors’ picks

  • Image 47: A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.

Image 48: Image attribution tooltipAdeline Kon / BioPharma Dive/BioPharma Dive Image 49: Image attribution tooltip Deep Dive //Patent thickets

Drug patents protect pharma profits. Track when they’ll expire.

BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

By Jonathan Gardner • Updated Aug. 4, 2026

  • Image 50: A sign reading Food and Drug Administration hangs over a building entrance.

Image 51: Image attribution tooltipYujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration Image 52: Image attribution tooltip Tracker

5 FDA decisions to watch in the fourth quarter of 2025

Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.

By BioPharma Dive staff • Updated Sept. 30, 2025

Latest in Pharma


Image 57: BioPharma Dive Logo

Explore

Reach our audience

Related Publications


Image 58: Informa TechTarget

This website is owned and operated by Informa TechTarget, a global network that informs, influences and connects the world’s technology buyers and sellers.

© 2026 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy | Terms of use | Take down policy | Cookie Preferences / Do Not Sell

Search Image 59

Image 60

Get BioPharma Dive in your inbox

The free newsletter covering the top industry headlines

Email:

  • Select Newsletter: - [x] Daily Dive M-F
  • Select Newsletter: - [x] Commercialization Weekly Every Wednesday
  • Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
  • Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
  • Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.

Sign up A valid email address is required. Please select at least one newsletter.

来源:BioPharma Dive · biopharmadive.com